You are here Home International Operations Overview
Overview

Intas' forte in delivering world-class products has earned it reputable presence in over 70 countries on the International pharmaceutical horizon, with 3000+ live product registrations. It has successfully augmented its R & D and manufacturing competency to enter into product alliances and strategic tie-ups and build business efficiencies for its partner companies. Intas customer base in Europe and US is multinational generic companies, retail pharma chains, distributors and hospitals. A territory specific marketing approach i.e. a mix of own marketing in select countries and tie ups with multinational companies in other markets, helps leverage its strong product basket and pipeline which also includes animal healthcare and biosimilar range of products.

Three of Intas’ biosimilar assets are already partnered for the EU, US, Canada, China and other markets. The first product for the regulated markets will be GCSF and is expected to be launched in Europe towards the end of 2013 by the company’s collaborator. Intas aims to be first Indian company to have enabled a commercialization of an indigenously developed biosimilar product in the regulated market. Intas’ biosimilar products are already commercialized in many emerging markets, through strategic marketing alliances. Several other biosimilar programs are at an advanced stage of development, and available for partnering discussions.

Intas is supported in its endeavours through its extensive network of branch offices and subsidiaries spanning USA, Canada, Europe, Central & Latin America, Africa, Asia-Pacific as well as CIS and MENA countries.